Evidence map›Paper›PMID 34242571›Full record

ArticleCancer cell2021

Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient.

Joshua A Hill, Chaitra S Ujjani, Alexander L Greninger, Mazyar Shadman, Ajay K Gopal

2 registry-linked trialsOpen access · bronzeAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 16 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 5 pooled it
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05205746 phase2completednot on this map

Phase II Study to Evaluate Immunogenicity and Safety in Subjects With Evidence of Prior Immunity to SARS-CoV-2 of a Single Intramuscular or Intranasal Dose of the Live Recombinant Newcastle Disease Virus Based AVX/COVID-12 Vaccine

TypeinterventionalSponsorLaboratorio Avi-Mex, S.A. de C.V.Ran2021 to 2023Enrolled158ConditionsSARS CoV 2 InfectionArmsRecombinant NDV Vectored Vaccine for SARS-CoV-2, Placebo
NCT05710783 phase2 / phase3completednot on this mapstarted 2022, after this paper: background citation

Phase II/III Parallel, Double-blind, Non-inferiority Study With Active Control, to Evaluate the Immunogenicity and Safety of a Booster Immunization Scheme With a Single Intramuscular Dose of the Recombinant Vaccine Against SARS-CoV-2

TypeinterventionalSponsorLaboratorio Avi-Mex, S.A. de C.V.Ran2022 to 2023Enrolled4,065ConditionsSARS-CoV-2 InfectionArmsAVX-COVID/12, ChAdOx-1-S[recombinant]
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 5 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Observational
  13. Observational
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Joshua A HillFred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington, Seattle, WA, USA; Seattle Cancer Care Alliance, Seattle, WA, USA. Electronic address: jahill3@fredhutch.org.
Chaitra S UjjaniFred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington, Seattle, WA, USA; Seattle Cancer Care Alliance, Seattle, WA, USA.
Alexander L GreningerFred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington, Seattle, WA, USA.
Mazyar ShadmanFred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington, Seattle, WA, USA; Seattle Cancer Care Alliance, Seattle, WA, USA.
Ajay K GopalFred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington, Seattle, WA, USA; Seattle Cancer Care Alliance, Seattle, WA, USA.
Fred Hutch Cancer Center · USSeattle Cancer Care Alliance · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19LymphomaCOVID-19 VaccinesHumansSARS-CoV-2VaccinationCOVID-19 VaccinesboosterCOVID-19hematologic malignancySARS-CoV-2vaccine

Identifiers

PMID34242571
PMCPMC8233960
OpenAlexW3175680112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.